Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 430-437

  Tofovic, Stevan P ^a   Salah, Eman M ^a,b   Mady, Hussam H ^a,b   Jackson, Edwin K ^a   Melhem, Mona F ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

17 Estradiol; Metabolites; Pulmonary arterial hypertension

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; CYCLINE; ESTRADIOL DERIVATIVE; MONOCROTALINE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MORTALITY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CELL PROLIFERATION; DISEASE PROGRESSION; ESTRADIOL; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MONOCROTALINE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TUBULIN MODULATORS;

EID: 26044447150     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000175878.32920.17     Document Type: Article

References (49)

1. Dresdale DT, Shultz M, Michtom RH. Primary pulmonary hypertension: I. Clinical and hemodynamic study. Am J Med. 1951;11:686-705.
2. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1959;21:557-570.
3. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a garget for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001;92:1-20.
4. Reid L. Vascular remodeling. In: Frishman AP, ed. The Pulmonary Circulation: Normal and Abnormal. Philadelphia: University of Pennsylvania Press; 1990:255-282.
5. Reeves JT, Bishop JE, Laurent GI. Functional basis for the structure of the pulmonary arterial tree. In: JE Bishop, Reeves JT, Laurent GJ, eds. Pulmonary Vascular Remodeling. London: Portland Press; 1995:1-19.
6. Tuder RM, Voelkel NF. Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal. 2002;4:833-843.
7. Dai-Do D, Espinosa E, Liu G, et al. 17β-Estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. Cardiovasc Res. 1996;32:980-985.
8. Fisher-Dzoga K, Wissler RW, Vesselinovich D. The effects of estradiol on the proliferation of rabbit aortic media tissue culture cells induced by hyperlipemic serum. Exp Mol Pathol. 1983;39:355-363.
9. Vargas R, Wroblewski B, Rego A, et al. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol. 1993;109:612-617.
10. 2+ mobilization. Circ Res. 1977;81:885-892.
11. 2 and NO in endothelial cells. Maturitas. 1996;25:141-147.
12. Sudhir K, Ko E, Zellner C, et al. Physiologic concentrations of estradiol attenuates endothelin 1-induced coronary vasoconstriction in vivo. Circulation. 1997;96:3626-3632.
13. Farhat MY, Chen MF, Bhatti T, et al. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharm. 1993;110:719-723.
14. Parker TA, Ivy DD, Galan HL, et al. Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2000;278:L374-L381.
15. Rabinovitch M, Gamble WJ, Miettinen OS, et al. Age and sex influence on pulmonary hypertension of chronic hypoxia and recovery. Am J Physiol Heart Circ Physiol. 1981;240:H62-H72.
16. Resta TC, Knaggy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol. 2001;280:L88-L97.
17. Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med. 2003;70: S2-S8.
18. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004;308:403-409.
19. Liu D, Bachmann KA. An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther. 1998;286:561-568.
20. Zacharia LC, Piche CA, Fielding RM, et al. 2-hydroxyestradiol is a prodrug of 2-methoxyestradiol. J Pharmacol Exp Ther. 2004;309:1093-1097.
21. Ball P, Emons G, Kayser H, et al. Metabolic clearance rates of catechol estrogens in rats. Endocrinology. 1983;113:1781-1783.
22. Lakham NJ, Sarkar MA, Venitz J, et al. 2-Methoxyestardiol, a promising anticancer drug. Pharmacotherapy. 2003;23:165-172.
23. LaVallee TM, Zhan XH, Herbstritt CJ, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002;62:3691-3697.
24. Seegers JC, Aveling MO, Van Aswegen CH, et al. The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and Hela Cells. J Steroid Biochem. 1989;32:797-809.
25. Nishigaki I, Sasaguri Y, Yagi K. Anti-proliferative effect of 2-methoxyestradiol on cultured smooth muscle cells from rabbit aorta. Atherosclerosis. 1995;113:167-170.
26. Dubey RK, Gillespie DG, Jackson EK, et al. 17β-estradiol, its metabolites and progesterone inhibit cardiac fibroblast growth. Hypertension. 1998;31:522-528.
27. Dubey RK, Gillespie DG, Zacharia LC, et al. Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun. 2000;278:27-33.
28. Dubey RK, Jackson EK, Keller PJ, et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension. 2001;37:640-644.
29. Seeger H, Mueck AO, Lippert TH. Effects of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci. 1999;65:167-170.
30. Tsukamoto A, Kaneko Y, Yoshida T, et al. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and beta-galactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun. 1998;248:9-12.
31. Voelkel NF, Cool C, Taraceviene-Stewart L, et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med. 2002;30:S251-S256.
32. Tofovic SP, Dubey RK, Jackson EK.2-Hydroxyestradiol attenuates the development of obesity, metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther. 2001;299:973-977.
33. Tofovic SP, Dubey R, Salah EM, et al. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol. 2002;13:2737-2747.
34. Tofovic SP, Salah EM, Dubey RK, et al. Estradiol metabolites attenuate renal injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol. 2005;46:25-35.
35. Tofovic SP, Maddy H, Jackson EK. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic angiotensin II administration [abstract]. Hypertension. 2003;42:414.
36. Tofovic SP, Jackson EK, Mady H.2-Methoxyestradiol attenuates hypertension and cardiac and vascular remodeling in constricted aorta rat model [abstract]. J Am Soc Nephrol. 2003;14:620A.
37. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rat by a serine elastase inhibitor. Nat Med. 2000;6:698-701.
38. Rosenberg H, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol. 1988;255: H1484-H1491.
39. Wilson DW, Segal HJ, Pan LC, et al. Mechanisms of pathology of monocrotaline toxicity. Crit Rev Toxicol. 1992;22:307-325.
40. Ball P, Knuppen R. Formation, metabolism, and physiological importance of catecholestrogens. Am J Obstet Gynecol. 1990;163:2163-2170.
41. 125I-labeled ligand. Acta Endocrinol. 1983;103:282-288.
42. Tofovic SP, Jackson EK, Zhang X.2-Methoxyestradiol mediates protective effects of estradiol in monocrotaline-induced pulmonary hypertension [abstract]. Circulation. 2004;110(suppl III):III-18.
43. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med. 1998;132:16-24.
44. Paunesku T, Mittal S, Protic M, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol. 2001;77:1007-1021.
45. Yue T-I, Wang X, Louden CS, et al. 2-Methopxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962.
46. Tinley TL, Leal RM, Randall-Hlubek DA, et al. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res. 2003;63:1538-1549.
47. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol. 2001;127:405-410.
48. Lippert C, Seeger H, Mueck AO, et al. The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sci. 2000;67:1653-1658.
49. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15:427-438.